The isoflavonoid tectorigenin has better antiplatelet potential than acetylsalicylic acid

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F17%3A10364319" target="_blank" >RIV/00216208:11160/17:10364319 - isvavai.cz</a>
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0944711317301113" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0944711317301113</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.phymed.2017.08.023" target="_blank" >10.1016/j.phymed.2017.08.023</a>

Result language
angličtina
Original language name
The isoflavonoid tectorigenin has better antiplatelet potential than acetylsalicylic acid
Original language description
Isoflavonoids seem to have positive activity on human cardiovascular health. One of the reasons can be their antiplatelet potential. In this study, we tested a series of structurally related isoflavonoids and we have shown that one of them, tectorigenin, has, at least, in ex vivo, conditions better antiplatelet effect than clinically used acetylsalicylic acid. The mechanism of action was also tested.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy

Project
<a href="/en/project/GBP303%2F12%2FG163" target="_blank" >GBP303/12/G163: Centre of drug-dietary supplements interactions and nutrigenetics</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)